Abstract Number: 412 • 2015 ACR/ARHP Annual Meeting
Update on the Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of the First 50 Patients at First Assessment. Www.Juvenile-Scleroderma.Com
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease. Currently just retrospective data exist regarding evolvement of organ involvement. In the previous retrospective studies…Abstract Number: 413 • 2015 ACR/ARHP Annual Meeting
Is There a Difference in the Presentation of Diffuse and Limited Subtype of Juvenile Systemic Sclerosis in Childhood? Results from the Juvenile Scleroderma Inception Cohort Www.Juvenile-Scleroderma.Com
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease. Several publications in adults looked at the differences between limited and diffuse subtypes. There is…Abstract Number: 414 • 2015 ACR/ARHP Annual Meeting
Performance of the Adult Systemic Sclerosis Classification in Juvenile Systemic Sclerosis Patients. Results from the Juvenile Systemic Sclerosis Inception Cohorte Www.Juvenile-Scleroderma.Com
Background/Purpose: The new adult classifiction criteria (1) for Systemic Sclerosis (SSc) were recently published and the pediatric criteria were published in 2007 (2). None of…Abstract Number: 415 • 2015 ACR/ARHP Annual Meeting
Development of a Juvenile Systemic Sclerosis Response Index (JSSRI)
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease. We have currently new promising effective medication to treat systemic sclerosis, but no valid outcome measures…Abstract Number: 416 • 2015 ACR/ARHP Annual Meeting
Prospective, Standardized, Longitudinal Assessment Reveals Higher Prevalence of Extracutaneous Manifestations in a Pediatric Localized Scleroderma Cohort
Background/Purpose: Localized scleroderma (LS) is an autoimmune condition whose hallmarks are progressive skin fibrosis and atrophy. However, LS is unique among skin diseases for its…Abstract Number: 417 • 2015 ACR/ARHP Annual Meeting
Gender Differences in Pediatric Localized Scleroderma: Clinical and Patient-Reported Outcomes
Background/Purpose: Localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissue that leads to progressive fibrosis and disability in growing children. Pediatric…Abstract Number: 418 • 2015 ACR/ARHP Annual Meeting
Relationship of Race, Ethnicity, and Outcomes in Pediatric Localized Scleroderma: Possible Differences in Disease Activity
Background/Purpose: Pediatric localized scleroderma (LS) is an autoimmune skin and soft tissue disease that causes morbidity via progressive skin fibrosis and extracutaneous manifestations (ECMs), such…Abstract Number: 419 • 2015 ACR/ARHP Annual Meeting
Development and Preliminary Validation of a New Composite Disease Activity Measure for Juvenile Dermatomyositis
Background/Purpose: Evaluation of the level of disease activity is a fundamental component of the clinical assessment of children with JDM. The global tools that are currently available for the assessment of the overall disease activity in JDM are centered on physician’s evaluation, neglecting parent’s or child’s perception. Furthermore, these instruments are lengthy and complex. There remains the need for a concise and easily administered tool that provides an absolute measure of disease activity for use in future trials in JDM. Aim of…Abstract Number: 420 • 2015 ACR/ARHP Annual Meeting
Description of the Juvenile Localized Scleroderma Subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory and fibrosing skin disease. We present baseline data on the juvenile LS (jLS) cohort from the Childhood…Abstract Number: 421 • 2015 ACR/ARHP Annual Meeting
Clinical Analysis and Outcome of Interstitial Lung Disease with Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myositis in children. It is a heterogeneous disease and clinical manifestations range from a relatively…Abstract Number: 422 • 2015 ACR/ARHP Annual Meeting
Mood Disorder Is Highly Prevalent in a Multi-Ethnic Urban Pediatric Lupus Cohort
Background/Purpose: While mood disorder, most commonly manifesting as depression and anxiety symptoms, is often reported in pediatric lupus patients, prevalence rates vary widely. Many published…Abstract Number: 423 • 2015 ACR/ARHP Annual Meeting
Institutional and Regional Variation in Childhood SLE 30-Day Hospital Readmission Rates: A Comparative Effectiveness Research Using the Pediatric Health Information System Database
Background/Purpose: Early hospital readmission is emerging as an indicator of care quality. The reported 30-day hospital readmission (30-DHR) rate for pediatric patients is 6.5%. However,…Abstract Number: 424 • 2015 ACR/ARHP Annual Meeting
Magnetic Resonance and Echocardiographic Strain Rate Imaging for the Early Detection of Cardiac Involvement in Juvenile Systemic Sclerosis
Background/Purpose: Cardiac involvement is one of the worst prognostic factors in JSSc. The diagnosis is usually based on clinical symptoms, EKG and conventional echocardiography, but…Abstract Number: 425 • 2015 ACR/ARHP Annual Meeting
Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus
Background/Purpose: Biopsy specimens of cutaneous neonatal lupus (cNL) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in connective…Abstract Number: 426 • 2015 ACR/ARHP Annual Meeting
The Risk of Hospitalized Infection Following Initiation of Biologic Agents Versus Methotrexate in the Treatment of Juvenile Idiopathic Arthritis
Background/Purpose: Biologic agents are highly effective for the treatment of juvenile idiopathic arthritis (JIA) but have the potential risk of increased serious infections. Using observational…
ACR Meeting Abstracts